Fibroblast Activation Protein alpha (FAP)
FAP, or fibroblast activation protein alpha, is a cell-surface serine protease that is widely studied in cancer biology and tumor microenvironment research.
FAP, or fibroblast activation protein alpha, is a cell-surface serine protease that is widely studied in cancer biology and tumor microenvironment research. It is of particular interest because of its association with activated fibroblasts and other stromal compartments in tumors, where it can serve as a biomarker and a therapeutic target. In biomedical research, FAP is often discussed in the context of tumor stroma remodeling, immune exclusion, and targeted delivery strategies.
As a protein target, FAP is notable for its expression pattern in certain malignancies and tumor-associated non-malignant cells, which can make it attractive for selective targeting approaches. In recent translational studies, FAP has been investigated as a target for engineered cell therapies, including chimeric antigen receptor T cells, with the goal of improving antitumor activity while exploiting its tumor-associated expression profile.
Where the papers sit
9 papers from the last 6 months study Fibroblast Activation Protein alpha (FAP) directly · updated from PubMed 13 Nov 2026
Study type 1 clinical trial · 5 preclinical · 3 unclassified
Themes one subject · 1 paradigm shift
Those 9 are all about one subject.
-
FAP Biology and Therapeutics
FAP research is expanding from diagnostic imaging toward targeted radiotherapy, immune-cell therapies, and nucleic acid delivery. Radioligands and PET/CT support localization and treatment of FAP-positive tumors, including glioblastoma and peritoneal carcinomatosis. UniCAR modules, in situ CAR-T and CAR-macrophage strategies aim to eliminate FAP-expressing tumor or stromal cells and remodel fibrotic tissue. Single-cell profiling and substrate studies are clarifying how activated fibroblasts and hepatic stellate cells shape cancer and liver fibrosis, but clinical validation remains open.
Multivalent FAP radioligands replace monomeric tracers as the effective design baseline
The glioblastoma-model study of glycosylated monomeric and dimeric FAP radioligands and the FAP/CAIX-positive tumor-model study of a heterodimeric radioligand challenge the assumption that a conventional monomeric FAP tracer provides sufficient tumor delivery. In the glioblastoma models, the dimeric tracer produced higher tumor uptake and superior tumor-to-nontarget ratios than both monomeric comparators, while the FAP/CAIX heterodimer showed greater uptake than monomeric tracers in FAP- or CAIX-positive tumors, with enhanced retention and therapeutic suppression after radioligand treatment 42343548Jun 42367011Jun. Together, these independent results make multivalent or dual-target engineering a functional requirement for improving FAP radiopharmaceutical accumulation, contrast, retention, and treatment efficacy rather than merely an incremental tracer modification.
Papers
The 9 papers from the last 6 months that study Fibroblast Activation Protein alpha (FAP) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
FAP Biology and Therapeutics (9)
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells. Oncoimmunology · 21 Aug 2026 PMID 42627862
- An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation. Nature materials · 12 Aug 2026 PMID 42587055
- Single-cell multi-omics deciphers the myofibro-inflammatory program of cancer-associated fibroblasts in triple-negative breast cancer. Cell death discovery · 11 Jul 2026 PMID 42436124
- PEG4-Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy. Journal of medicinal chemistry · 29 Jun 2026 PMID 42367011
- Development of Glycosylated and Dimeric FAP-Targeted Radiotracers for Preclinical Evaluation in FAP-Positive Glioblastoma Models. Journal of medicinal chemistry · 25 Jun 2026 PMID 42343548
- FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782
- Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease. Scandinavian journal of gastroenterology · 3 Jun 2026 PMID 42233208
- mRNA-laden LNP-enabled in situ CAR-macrophage alleviates liver fibrosis via inhibiting activated HSCs and modulating the immune microenvironment. Proceedings of the National Academy of Sciences of the United States of America · 29 May 2026 PMID 42213756
- Preoperative Assessment of Peritoneal Carcinomatosis with [68Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [18F]FDG PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 21 May 2026 PMID 42167805
By study type
Clinical trials (1)
- Preoperative Assessment of Peritoneal Carcinomatosis with [68Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [18F]FDG PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 21 May 2026 PMID 42167805
Preclinical: animal, cell and lab studies (5)
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells. Oncoimmunology · 21 Aug 2026 PMID 42627862
- PEG4-Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy. Journal of medicinal chemistry · 29 Jun 2026 PMID 42367011
- Development of Glycosylated and Dimeric FAP-Targeted Radiotracers for Preclinical Evaluation in FAP-Positive Glioblastoma Models. Journal of medicinal chemistry · 25 Jun 2026 PMID 42343548
- FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782
- mRNA-laden LNP-enabled in situ CAR-macrophage alleviates liver fibrosis via inhibiting activated HSCs and modulating the immune microenvironment. Proceedings of the National Academy of Sciences of the United States of America · 29 May 2026 PMID 42213756
Unclassified: not yet indexed with MeSH (3)
- An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation. Nature materials · 12 Aug 2026 PMID 42587055
- Single-cell multi-omics deciphers the myofibro-inflammatory program of cancer-associated fibroblasts in triple-negative breast cancer. Cell death discovery · 11 Jul 2026 PMID 42436124
- Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease. Scandinavian journal of gastroenterology · 3 Jun 2026 PMID 42233208
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.